566 related articles for article (PubMed ID: 36640224)
1. Role of myeloid-derived suppressor cells in tumor recurrence.
Cole K; Al-Kadhimi Z; Talmadge JE
Cancer Metastasis Rev; 2023 Mar; 42(1):113-142. PubMed ID: 36640224
[TBL] [Abstract][Full Text] [Related]
2. Role of myeloid-derived suppressor cells in metastasis.
Cole K; Pravoverov K; Talmadge JE
Cancer Metastasis Rev; 2021 Jun; 40(2):391-411. PubMed ID: 33411082
[TBL] [Abstract][Full Text] [Related]
3. Myeloid derived suppressor cells and the release of micro-metastases from dormancy.
Khadge S; Cole K; Talmadge JE
Clin Exp Metastasis; 2021 Jun; 38(3):279-293. PubMed ID: 34014424
[TBL] [Abstract][Full Text] [Related]
4. Sponge-like nano-system suppresses tumor recurrence and metastasis by restraining myeloid-derived suppressor cells-mediated immunosuppression and formation of pre-metastatic niche.
Xia C; Bai W; Deng T; Li T; Zhang L; Lu Z; Zhang Z; Li M; He Q
Acta Biomater; 2023 Mar; 158():708-724. PubMed ID: 36638937
[TBL] [Abstract][Full Text] [Related]
5. Visualization and quantification of
Hoffmann SHL; Reck DI; Maurer A; Fehrenbacher B; Sceneay JE; Poxleitner M; Öz HH; Ehrlichmann W; Reischl G; Fuchs K; Schaller M; Hartl D; Kneilling M; Möller A; Pichler BJ; Griessinger CM
Theranostics; 2019; 9(20):5869-5885. PubMed ID: 31534525
[TBL] [Abstract][Full Text] [Related]
6. MDSCs: Key Criminals of Tumor Pre-metastatic Niche Formation.
Wang Y; Ding Y; Guo N; Wang S
Front Immunol; 2019; 10():172. PubMed ID: 30792719
[TBL] [Abstract][Full Text] [Related]
7. Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.
Dysthe M; Parihar R
Adv Exp Med Biol; 2020; 1224():117-140. PubMed ID: 32036608
[TBL] [Abstract][Full Text] [Related]
8. CXCL17-derived CD11b
Hsu YL; Yen MC; Chang WA; Tsai PH; Pan YC; Liao SH; Kuo PL
Breast Cancer Res; 2019 Feb; 21(1):23. PubMed ID: 30755260
[TBL] [Abstract][Full Text] [Related]
9. Circulating myeloid-derived suppressor cells: An independent prognostic factor in patients with breast cancer.
Safarzadeh E; Hashemzadeh S; Duijf PHG; Mansoori B; Khaze V; Mohammadi A; Kazemi T; Yousefi M; Asadi M; Mohammadi H; Babaie F; Baradaran B
J Cell Physiol; 2019 Apr; 234(4):3515-3525. PubMed ID: 30362521
[TBL] [Abstract][Full Text] [Related]
10. The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion.
De Cicco P; Ercolano G; Ianaro A
Front Immunol; 2020; 11():1680. PubMed ID: 32849585
[TBL] [Abstract][Full Text] [Related]
11. Myeloid-derived suppressor cells: The green light for myeloma immune escape.
Malek E; de Lima M; Letterio JJ; Kim BG; Finke JH; Driscoll JJ; Giralt SA
Blood Rev; 2016 Sep; 30(5):341-8. PubMed ID: 27132116
[TBL] [Abstract][Full Text] [Related]
12. Myeloid-derived suppressor cells: Important contributors to tumor progression and metastasis.
Safarzadeh E; Orangi M; Mohammadi H; Babaie F; Baradaran B
J Cell Physiol; 2018 Apr; 233(4):3024-3036. PubMed ID: 28661031
[TBL] [Abstract][Full Text] [Related]
13. Targeting myeloid-derived suppressor cells in combination with tumor cell vaccination predicts anti-tumor immunity and breast cancer dormancy: an in silico experiment.
Mehdizadeh R; Shariatpanahi SP; Goliaei B; Rüegg C
Sci Rep; 2023 Apr; 13(1):5875. PubMed ID: 37041172
[TBL] [Abstract][Full Text] [Related]
14. Circulating Myeloid-Derived Suppressor Cell Subsets in Patients with Colorectal Cancer - Exploratory Analysis of Their Biomarker Potential.
Fědorová L; Pilátová K; Selingerová I; Bencsiková B; Budinská E; Zwinsová B; Brychtová V; Langrová M; Šefr R; Valík D; Zdražilová Dubská L
Klin Onkol; 2018; 31(Suppl 2):88-92. PubMed ID: 31023030
[TBL] [Abstract][Full Text] [Related]
15. The Role of Myeloid-Derived Suppressor Cells in Tumor Growth and Metastasis.
Bayik D; Lee J; Lathia JD
Exp Suppl; 2022; 113():189-217. PubMed ID: 35165865
[TBL] [Abstract][Full Text] [Related]
16. Reciprocal relationship between cancer stem cells and myeloid-derived suppressor cells: implications for tumor progression and therapeutic strategies.
Ding G; Yu H; Jin J; Qiao X; Ma J; Zhang T; Cheng X
Future Oncol; 2024 Feb; 20(4):215-228. PubMed ID: 38390682
[TBL] [Abstract][Full Text] [Related]
17. Minimal residual disease in advanced or metastatic solid cancers: The G0-G1 state and immunotherapy are key to unwinding cancer complexity.
Nicolini A; Rossi G; Ferrari P; Carpi A
Semin Cancer Biol; 2022 Feb; 79():68-82. PubMed ID: 32201368
[TBL] [Abstract][Full Text] [Related]
18. Myeloid-Derived Suppressor-Cell Dynamics Control Outcomes in the Metastatic Niche.
Kreger J; Roussos Torres ET; MacLean AL
Cancer Immunol Res; 2023 May; 11(5):614-628. PubMed ID: 36848523
[TBL] [Abstract][Full Text] [Related]
19. Targeting Myeloid-Derived Suppressor Cells for Premetastatic Niche Disruption After Tumor Resection.
Tang F; Tie Y; Hong W; Wei Y; Tu C; Wei X
Ann Surg Oncol; 2021 Jul; 28(7):4030-4048. PubMed ID: 33258011
[TBL] [Abstract][Full Text] [Related]
20. PMN-MDSCs Enhance CTC Metastatic Properties through Reciprocal Interactions via ROS/Notch/Nodal Signaling.
Sprouse ML; Welte T; Boral D; Liu HN; Yin W; Vishnoi M; Goswami-Sewell D; Li L; Pei G; Jia P; Glitza-Oliva IC; Marchetti D
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31003475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
